Not yet independently audited
This page was written from verified sources but has not yet passed the independent citation audit. Treat its claims as provisional.
Post-traumatic stress disorder — master index¶
Last curated: 2026-10-23 (Grok sweep; independent audit pending) · 9 curated + 13 draft wiki pages · 434 unique PMIDs (422 previously catalogued + 12 this sweep; flagged integrity records remain documentation only) · 6 landmark notes · 11 guideline records · 22 cited NCT records re-fetched live on 2026-10-23 · 9 organizations listed · 17 open questions + 21 unconnected-dot junctions
The condition in five sentences. PTSD is a trauma- and stressor-related disorder defined by a qualifying exposure, a patterned syndrome, persistence and impairment—not by trauma exposure alone. DSM-5 and ICD-11 identify overlapping but non-identical cases, and ICD-11 adds complex PTSD, leaving a live transportability problem for trials built under DSM definitions (Cloitre 2018, PMID 30178492). Trauma-focused CBT variants and EMDR have the strongest comparative evidence, but active-comparator differences, dropout and long-term function are less certain than waitlist-referenced symptom effects (Mavranezouli 2020, PMID 32063234; McLean 2022, PMID 34954460). Medication evidence is narrower — SSRIs improve response versus placebo (RR 0.66, 95% CI 0.59–0.74) but only sertraline and paroxetine are FDA-approved — and prazosin illustrates unresolved heterogeneity, because three positive trials and two meta-analyses favouring it sit alongside a 304-person null re-test (Williams 2022, PMID 35234292; Raskind 2018, PMID 29414272; Yücel 2020, PMID 31855732). MDMA-assisted therapy produced two positive phase 3 trials, but the FDA declined approval in August 2024 and required another phase 3 trial, so efficacy, safety, blinding and regulation remain separate questions (Mitchell 2021, PMID 33972795; Mitchell 2023, PMID 37709999; Morland 2026, PMID 41820235). Three sponsor-authored pooled phase 2 analyses were retracted in 2024; none is cited here as evidence (Mithoefer 2024, PMID 39126501).
Start here: overview. Research frontier: OPEN-QUESTIONS.md. Growth history: LOG.md.
Scope and pooling rule¶
- PTSD owns the disorder, not trauma exposure in general.
- PTSD and generalized anxiety disorder are neighbours, not subsets. Mixed-anxiety estimates are labelled and only PTSD strata are used as PTSD effects.
- Comorbid depression is cross-linked rather than absorbed.
- Complex PTSD is in scope as an ICD-11 sibling diagnosis and unresolved treatment-transport problem.
Reading paths¶
- Clinical: overview → diagnosis → comparative psychotherapy → pharmacotherapy → guidelines → safety
- Therapy: prolonged exposure → cognitive processing therapy → EMDR → dropout/nonresponse
- Science: epidemiology/risk → neurobiology → complex PTSD → comorbidity
- Populations: military/veterans → children/adolescents → patient experience
- Frontier: open questions → MDMA/psychedelics → trials landscape
Wiki pages¶
| Section | Page | Scope | Status |
|---|---|---|---|
| Overview | overview.md | Post-traumatic stress disorder — Overview | curated |
| Diagnosis | diagnosis-and-classification.md | PTSD — Diagnosis and classification | draft — edited at 2026-10-23 sweep, awaiting audit |
| Complex-Ptsd | complex-ptsd.md | Complex PTSD | draft — demoted at 2026-10-23 sweep, awaiting audit |
| Epidemiology | epidemiology-and-risk.md | PTSD — Epidemiology and risk | curated |
| Neurobiology | neurobiology-and-mechanism.md | PTSD — Neurobiology and mechanism | curated |
| Prolonged-Exposure | prolonged-exposure.md | Prolonged exposure for PTSD | curated |
| Cognitive-Processing-Therapy | cognitive-processing-therapy.md | Cognitive processing therapy for PTSD | curated |
| Emdr | emdr.md | Eye movement desensitization and reprocessing | curated |
| Psychotherapy | comparative-psychotherapy-evidence.md | PTSD — Comparative psychotherapy evidence | draft — edited at 2026-10-09 sweep, awaiting audit |
| Dropout | dropout-and-nonresponse.md | PTSD treatment dropout and nonresponse | draft — edited at 2026-10-09 sweep, awaiting audit |
| Pharmacotherapy | pharmacotherapy.md | PTSD pharmacotherapy | draft — edited at 2026-10-09 sweep, awaiting audit |
| Sleep | sleep-and-nightmare-treatment.md | PTSD sleep and nightmare treatment | curated |
| Mdma | mdma-and-psychedelic-assisted-therapy.md | MDMA and psychedelic-assisted therapy for PTSD | draft — edited at 2026-10-23 sweep, awaiting audit |
| Prevention | early-intervention-and-prevention.md | PTSD early intervention and prevention | draft — edited at 2026-10-09 sweep, awaiting audit |
| Military | military-and-veteran-populations.md | PTSD in military and veteran populations | draft — demoted at 2026-10-23 sweep, awaiting audit |
| Children | children-and-adolescents.md | PTSD in children and adolescents | draft — edited at 2026-10-09 sweep, awaiting audit |
| Comorbidity | comorbidity.md | PTSD comorbidity | draft — edited at 2026-10-23 sweep, awaiting audit |
| Moral-Injury | moral-injury.md | Moral injury and PTSD | curated |
| Guidelines | guidelines.md | PTSD clinical practice guidelines | draft — see audit note |
| Safety | red-flags-and-safety-concerns.md | PTSD red flags and safety concerns | draft — demoted at 2026-10-23 sweep, awaiting audit |
| Patient-Experience | patient-experience-and-advocacy.md | PTSD patient experience and advocacy | curated |
| Clinical-Trials | clinical-trials-landscape.md | PTSD clinical trials landscape | draft — edited at 2026-10-23 sweep, awaiting audit |
Literature layer¶
| Artifact | Contents | Status |
|---|---|---|
| BIBLIOGRAPHY.md | 434 unique live-retrieved PubMed records; tags and cited-by index | draft |
| notes/ | 6 landmark deep notes | curated |
| guidelines/REGISTRY.md | Current and superseded international guidance; disagreements and watch list | draft |
| statistics/STATISTICS.md | Definition-preserving quantitative reference tables | draft |
| patient-voice/ | Ethics/method, 9 organizations, 10 themes, annotated sources | curated |
Curation state¶
The 22 pages were written by Codex from live PubMed E-utilities and ClinicalTrials.gov v2 queries on 2026-09-02, then independently audited by Claude on the same date. No model audited its own writing.
The audit re-fetched all 385 PMIDs and 15 NCT IDs live, checked 659 reference lines, 655 evidence-ledger rows and every claim-to-citation pair on every page, re-ran the searches behind each asserted absence, and fixed what was wrong rather than only reporting it. 21 pages passed and are now status: curated.
guidelines.md remains draft for one specific reason: three of its load-bearing facts rest on issuing-body web pages rather than PubMed records, and those could not be independently re-fetched from the audit session — healthquality.va.gov failed at the TLS layer, and istss.org returned its content client-side so the 361-RCT/208-meta-analysis/125-recommendation counts could not be read from the raw HTML. The VA/DoD guideline has since been re-anchored to its peer-reviewed synopsis (Schnurr 2024, PMID 38408360), which independently confirms the 34-recommendation figure. Separately, NICE's NG116 evidence page lists a July 2026 exceptional surveillance whose decision document returned HTTP 403; until its outcome is known, describing NG116 as unchanged since April 2025 would be an assumption rather than a finding. That is the first item for the next sweep.
2026-10-23 sweep (Grok). Twelve PubMed records were added. Complex PTSD, military and veteran populations, and safety were demoted to draft because their text changed. Diagnosis, comorbidity, MDMA and psychedelics, and the trials landscape were already draft and were edited again. The NICE evidence index was re-checked and still lists the July 2026 exceptional surveillance as its latest entry; the decision document was not re-opened. No page was promoted. An independent audit is pending.